Xtl Biopharmaceuticals (XTLB) Retained Earnings (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Retained Earnings for 17 consecutive years, with -$165.6 million the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings fell 4.17% year-over-year to -$165.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$165.6 million (down 4.17% YoY) and the FY2025 annual result came in at -$165.6 million, down 4.17% from the prior year.
• Retained Earnings slipped to -$165.6 million in Q4 2025 per XTLB's latest filing, from -$164.5 million in the prior quarter.
• Over the last five years, Retained Earnings for XTLB reached as high as -$154.9 million in Q2 2022 and fell as low as -$165.6 million in Q4 2025.
• A 5-year average of -$158.3 million and a median of -$157.8 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings increased 0.99% — and 2025, when it slipped 4.17%.
• Year by year, Retained Earnings stood at -$155.1 million in 2021, then slipped by 0.86% to -$156.5 million in 2022, then fell by 1.14% to -$158.2 million in 2023, then retreated by 0.48% to -$159.0 million in 2024, then slipped by 4.17% to -$165.6 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$165.6 million, -$164.5 million, and -$159.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.